160 related articles for article (PubMed ID: 18084610)
1. In vivo evaluation of AT-101 (R-(-)-gossypol acetic acid) in androgen-independent growth of VCaP prostate cancer cells in combination with surgical castration.
Loberg RD; McGregor N; Ying C; Sargent E; Pienta KJ
Neoplasia; 2007 Dec; 9(12):1030-7. PubMed ID: 18084610
[TBL] [Abstract][Full Text] [Related]
2. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
McGregor N; Patel L; Craig M; Weidner S; Wang S; Pienta KJ
J Cell Biochem; 2010 Aug; 110(5):1187-94. PubMed ID: 20589722
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation.
Lian J; Ni Z; Dai X; Su C; Smith AR; Xu L; He F
Mol Cancer Ther; 2012 Feb; 11(2):416-26. PubMed ID: 22188816
[TBL] [Abstract][Full Text] [Related]
4. Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.
Meng Y; Tang W; Dai Y; Wu X; Liu M; Ji Q; Ji M; Pienta K; Lawrence T; Xu L
Mol Cancer Ther; 2008 Jul; 7(7):2192-202. PubMed ID: 18645028
[TBL] [Abstract][Full Text] [Related]
5. Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer.
Jackson RS; Placzek W; Fernandez A; Ziaee S; Chu CY; Wei J; Stebbins J; Kitada S; Fritz G; Reed JC; Chung LW; Pellecchia M; Bhowmick NA
Neoplasia; 2012 Jul; 14(7):656-65. PubMed ID: 22904682
[TBL] [Abstract][Full Text] [Related]
6. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.
Gleave ME; Miayake H; Goldie J; Nelson C; Tolcher A
Urology; 1999 Dec; 54(6A Suppl):36-46. PubMed ID: 10606283
[TBL] [Abstract][Full Text] [Related]
7. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.
Leung S; Miyake H; Zellweger T; Tolcher A; Gleave ME
Int J Cancer; 2001 Mar; 91(6):846-50. PubMed ID: 11275990
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.
Miayake H; Tolcher A; Gleave ME
J Natl Cancer Inst; 2000 Jan; 92(1):34-41. PubMed ID: 10620631
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice.
Tang Y; Khan MA; Goloubeva O; Lee DI; Jelovac D; Brodie AM; Hussain A
Clin Cancer Res; 2006 Jan; 12(1):169-74. PubMed ID: 16397039
[TBL] [Abstract][Full Text] [Related]
10. A natural BH3 mimetic induces autophagy in apoptosis-resistant prostate cancer via modulating Bcl-2-Beclin1 interaction at endoplasmic reticulum.
Lian J; Wu X; He F; Karnak D; Tang W; Meng Y; Xiang D; Ji M; Lawrence TS; Xu L
Cell Death Differ; 2011 Jan; 18(1):60-71. PubMed ID: 20577262
[TBL] [Abstract][Full Text] [Related]
11. LIGHT sensitizes IFNgamma-mediated apoptosis of MDA-MB-231 breast cancer cells leading to down-regulation of anti-apoptosis Bcl-2 family members.
Zhang M; Guo R; Zhai Y; Yang D
Cancer Lett; 2003 Jun; 195(2):201-10. PubMed ID: 12767529
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
13. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
Gleave M; Tolcher A; Miyake H; Nelson C; Brown B; Beraldi E; Goldie J
Clin Cancer Res; 1999 Oct; 5(10):2891-8. PubMed ID: 10537358
[TBL] [Abstract][Full Text] [Related]
14. (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer.
Xu L; Yang D; Wang S; Tang W; Liu M; Davis M; Chen J; Rae JM; Lawrence T; Lippman ME
Mol Cancer Ther; 2005 Feb; 4(2):197-205. PubMed ID: 15713891
[TBL] [Abstract][Full Text] [Related]
15. Preclinical studies of apogossypolone, a novel pan inhibitor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells.
Banerjee S; Choi M; Aboukameel A; Wang Z; Mohammad M; Chen J; Yang D; Sarkar FH; Mohammad RM
Pancreas; 2010 Apr; 39(3):323-31. PubMed ID: 19823097
[TBL] [Abstract][Full Text] [Related]
16. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.
Yamanaka K; Rocchi P; Miyake H; Fazli L; Vessella B; Zangemeister-Wittke U; Gleave ME
Mol Cancer Ther; 2005 Nov; 4(11):1689-98. PubMed ID: 16275990
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
[TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis and antitumor effects of a small molecule inhibitor of Bcl-2 and Bcl-xl, gossypol acetate, in multiple myeloma in vitro and in vivo.
Lin J; Wu Y; Yang D; Zhao Y
Oncol Rep; 2013 Aug; 30(2):731-8. PubMed ID: 23708869
[TBL] [Abstract][Full Text] [Related]
19. Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins.
Nickerson T; Miyake H; Gleave ME; Pollak M
Cancer Res; 1999 Jul; 59(14):3392-5. PubMed ID: 10416600
[TBL] [Abstract][Full Text] [Related]
20. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer.
Liu G; Kelly WK; Wilding G; Leopold L; Brill K; Somer B
Clin Cancer Res; 2009 May; 15(9):3172-6. PubMed ID: 19366825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
